Literature DB >> 15859311

HPV triage of women with atypical squamous cells of undetermined significance: a 3-year experience in an Italian organized programme.

P Dalla Palma1, A Pojer, S Girlando.   

Abstract

OBJECTIVE: The purpose of our study was to determine if Hybrid Capture II assay (HCII) on Liquid Based Cytology (LCB) improves the accuracy (higher sensitivity, similar specificity) than the repeat conventional Pap smear in smears with Atypical Squamous Cell (ASC) of Undetermined Significance diagnosis.
METHODS: HPV testing was used to manage women, especially the older ones, with cervical abnormalities detected through our triennial organized screening in order to avoid unnecessary colposcopy and excessive follow-up if the woman is HPV negative. The HPV DNA Triage was offered without any charge to 909 women with ASC. The Bethesda System was used for the classification of these equivocal cytological findings and more precisely the 1991 version (ASCUS) until the summer 2001 (315 cases) and the new one 2001 classification (ASC-US and ASC-H) after this date (594 cases). The presence or absence of a cervical intraepithelial neoplasia of grade I or worse [CIN1+], and of grade II or worse [CIN2+], was confirmed by biopsy.
RESULTS: The HPV DNA Triage showed a good accuracy (specificity over 94%, sensitivity of 37% and PPV for CIN2+ lesions around 30%). The higher values of ASC-H lesions (.462) for the sensitivity for CIN 2+ probably signify that this lesion is already a SIL.
CONCLUSIONS: Our data were comparable with those recently published on the meta-analysis by Arbyn et al., confirming the promising approach of our guidelines for the treatment of these patients even in terms of Health Technology Assessment (HTA).

Entities:  

Mesh:

Year:  2005        PMID: 15859311     DOI: 10.1111/j.1365-2303.2004.00196.x

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  4 in total

1.  SNIPER: a novel assay for human papillomavirus testing among women in Guizhou, China.

Authors:  Suzanne E Belinson; Na Wulan; Ruizhen Li; Wei Zhang; Xuan Rong; Yasha Zhu; Ruifang Wu; Jerome L Belinson
Journal:  Int J Gynecol Cancer       Date:  2010-08       Impact factor: 3.437

2.  Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.

Authors:  Francesca Carozzi; Simonetta Bisanzi; Cristina Sani; Marco Zappa; Silvia Cecchini; Stefano Ciatto; Massimo Confortini
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

3.  Comparison of the DiagCor GenoFlow Human Papillomavirus Array Test and Roche Linear Array HPV Genotyping Test.

Authors:  Fiona K Y Wong; Johannes C Y Ching; Joseph K F Chow
Journal:  Open Virol J       Date:  2010-11-03

4.  Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate.

Authors:  Marc Arbyn; Pierre Martin-Hirsch; Frank Buntinx; Marc Van Ranst; Evangelos Paraskevaidis; Joakim Dillner
Journal:  J Cell Mol Med       Date:  2009-01-23       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.